A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)

Trial Profile

A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Pritelivir (Primary) ; Foscarnet
  • Indications Herpes simplex virus infections
  • Focus Therapeutic Use
  • Acronyms PRIOH-1
  • Sponsors AiCuris
  • Most Recent Events

    • 09 May 2017 Status changed from not yet recruiting to recruiting.
    • 25 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
    • 13 Apr 2017 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top